https://biodexapharma.com/biodexa-pharmaceuticals-plc-announces-closing-of-3-32-million-registered-direct-offering/ 2023-05-26T20:05:00+00:00 https://biodexapharma.com/wp-content/uploads/Biodexa-Pharmaceuticals-PLC-yqox79.gif https://biodexapharma.com/mtx110-update-headline-results-for-2020/ 2023-05-30T15:13:46+00:00 https://biodexapharma.com/midatech-pharma-welcomes-dr-dmitry-zamoryakhin-as-chief-scientific-officer/ 2023-05-30T15:14:15+00:00 https://biodexapharma.com/wp-content/uploads/Dmitry-Zamoryakhin.jpg https://biodexapharma.com/ind-application-for-mtx110-study-in-gbm-effective/ 2023-05-30T15:22:34+00:00 https://biodexapharma.com/first-patient-enrolled-in-phase-1-study-of-mtx-110-magic-g1-study-in-patients-with-recurrent-glioblastoma/ 2023-05-30T15:23:10+00:00 https://biodexapharma.com/an-update-to-mtx110-study-in-pediatric-patients-with-dipg/ 2023-05-30T15:23:25+00:00 https://biodexapharma.com/fast-track-designation-granted-to-mtx110-development-for-the-treatment-of-recurrent-glioblastoma/ 2023-05-30T15:23:57+00:00 https://biodexapharma.com/biodexa-pharmaceuticals-plc-announces-us3-32-million-registered-direct-offering/ 2023-05-30T15:24:54+00:00 https://biodexapharma.com/wp-content/uploads/Biodexa-Pharmaceuticals-PLC-x8UNbY.gif https://biodexapharma.com/posting-of-annual-report-notice-of-agm/ 2023-05-30T15:25:10+00:00 https://biodexapharma.com/wp-content/uploads/Biodexa-Pharmaceuticals-PLC-yGRhyP.gif https://biodexapharma.com/biodexa-pharmaceuticals-enters-into-non-binding-letter-of-intent-for-proposed-acquisition-of-varian-biopharmaceuticals/ 2023-05-30T15:25:30+00:00 https://biodexapharma.com/wp-content/uploads/Biodexa-Pharmaceuticals-PLC-4Nw8MS.gif https://biodexapharma.com/preliminary-results-for-the-year-ended-31-december-2022/ 2023-05-30T15:25:59+00:00 https://biodexapharma.com/wp-content/uploads/18e06e3a-a23a-4f17-b1e7-276abf35acc0-NeilR1.png https://biodexapharma.com/planned-dose-escalation-in-phase-1-study-of-mtx-110-magic-g1-study-in-patients-with-recurrent-glioblastoma/ 2023-05-30T15:26:42+00:00 https://biodexapharma.com/orphan-designation-granted-by-ema-to-mtx110-development-for-the-treatment-of-glioma/ 2023-05-30T15:47:00+00:00 https://biodexapharma.com/private-placement-raising-us6-0-million/ 2023-05-30T17:09:43+00:00 https://biodexapharma.com/closing-of-6-0m-private-placement-broker-change/ 2023-05-30T17:09:48+00:00 https://biodexapharma.com/breakthrough-data-using-q-sphera-technology/ 2023-05-30T17:10:02+00:00 https://biodexapharma.com/uk-parliament-highlights-need-for-new-dipg-treatments/ 2023-05-30T17:10:15+00:00 https://biodexapharma.com/uk-placing-to-raise-5-0-million/ 2023-06-01T09:36:07+00:00 https://biodexapharma.com/collaboration-for-the-q-sphera-platform/ 2023-06-01T09:36:28+00:00 https://biodexapharma.com/research-collaboration-with-dr-reddys/ 2023-06-01T09:36:34+00:00 https://biodexapharma.com/midatechs-mtx110-receives-orphan-designation-for-dipg/ 2023-06-01T09:37:18+00:00 https://biodexapharma.com/headline-results-of-mtx110-phase-i-dipg-study/ 2023-06-01T09:37:24+00:00 https://biodexapharma.com/uk-placing-to-raise-1-8-million/ 2023-06-01T09:49:38+00:00 https://biodexapharma.com/us3-0-million-registered-direct-offering/ 2023-06-01T09:50:19+00:00 https://biodexapharma.com/closing-of-us3-0m-registered-direct-offering/ 2023-06-01T09:50:38+00:00 https://biodexapharma.com/results-of-annual-general-meeting-and-general-meeting/ 2023-06-14T12:30:00+00:00 https://biodexapharma.com/wp-content/uploads/Biodexa-Pharmaceuticals-PLC-YwMCOH.gif https://biodexapharma.com/receipt-of-nasdaq-delisting-determination-plans-to-appeal/ 2023-06-15T20:05:00+00:00 https://biodexapharma.com/wp-content/uploads/Biodexa-Pharmaceuticals-PLC-DaIIBB.gif https://biodexapharma.com/appeal-of-delisting-determination/ 2023-06-20T12:00:00+00:00 https://biodexapharma.com/wp-content/uploads/Biodexa-Pharmaceuticals-PLC-FWtXjt.gif https://biodexapharma.com/adr-ratio-change/ 2023-06-22T20:15:00+00:00 https://biodexapharma.com/wp-content/uploads/Biodexa-Pharmaceuticals-PLC-Ds4dwP.gif https://biodexapharma.com/publication-of-manuscript-from-the-pnoc015-a-k-a-mtd-201-study-in-patients-with-diffuse-midline-glioma-dmg/ 2023-07-06T12:15:00+00:00 https://biodexapharma.com/wp-content/uploads/Biodexa-Pharmaceuticals-PLC-nUwRZF.gif https://biodexapharma.com/results-of-appeal-of-delisting-determination/ 2023-07-06T20:30:00+00:00 https://biodexapharma.com/wp-content/uploads/Biodexa-Pharmaceuticals-PLC-3Ruapa.gif https://biodexapharma.com/completion-of-enrolment-and-treatment-in-the-phase-1-study-of-mtx110-in-the-treatment-of-children-with-newly-diagnosed-diffuse-midline-gliomas-dmgs/ 2023-07-10T12:00:00+00:00 https://biodexapharma.com/wp-content/uploads/Biodexa-Pharmaceuticals-PLC-2Mg1xd.gif https://biodexapharma.com/biodexa-regain-compliance-with-nasdaq-minimum-bid-price-requirement/ 2023-07-24T11:30:00+00:00 https://biodexapharma.com/wp-content/uploads/Biodexa-Pharmaceuticals-PLC-u7SR0b.gif https://biodexapharma.com/biodexa-pharmaceuticals-launches-new-corporate-and-clinical-trials-websites/ 2023-07-28T14:06:08+00:00 https://biodexapharma.com/wp-content/uploads/Biodexa-Pharmaceuticals-PLC-NQeafW.gif https://biodexapharma.com/mtx110-presented-at-2020-annual-sno-conference/ 2023-08-08T14:25:25+00:00 https://biodexapharma.com/mtx110-programmes-to-be-presented-at-ispno-2020/ 2023-08-08T14:27:02+00:00 https://biodexapharma.com/targeting-technology-offers-hope-for-cancer-patients/ 2023-08-08T14:38:45+00:00 https://biodexapharma.com/wp-content/uploads/times-raconteur-reports-logos-stacked.png https://biodexapharma.com/biodexa-to-present-recruitment-and-treatment-update-in-phase-1-study-of-mtx-110-magic-g1-study-in-patients-with-recurrent-glioblastoma-at-2023-annual-european-association-of-neuro-oncology-meeting/ 2023-09-21T12:30:00+00:00 https://biodexapharma.com/wp-content/uploads/Biodexa-Pharmaceuticals-PLC-RHUGsz.gif https://biodexapharma.com/interim-results-for-the-six-months-ended-30-june-2023/ 2023-09-29T20:30:00+00:00 https://biodexapharma.com/wp-content/uploads/Biodexa-Pharmaceuticals-PLC-rqcceP.gif https://biodexapharma.com/biodexa-enters-into-agreements-to-acquire-exclusive-worldwide-license-to-tolimidone-a-phase-ii-ready-asset-for-type-1-diabetes/ 2023-11-27T14:00:00+00:00 https://biodexapharma.com/wp-content/uploads/Biodexa-Pharmaceuticals-PLC-xMCSI2.gif https://biodexapharma.com/biodexa-completes-recruitment-of-cohort-a-in-study-of-mtx110-in-patients-with-recurrent-glioblastoma/ 2023-11-30T14:09:36+00:00 https://biodexapharma.com/wp-content/uploads/Biodexa-Pharmaceuticals-PLC-EWHaes.gif https://biodexapharma.com/biodexa-announces-pricing-of-5-2-million-underwritten-public-offering/ 2023-12-19T13:42:00+00:00 https://biodexapharma.com/wp-content/uploads/Biodexa-Pharmaceuticals-PLC-BP0JTp.gif https://biodexapharma.com/biodexa-announces-closing-of-6-0-million-underwritten-public-offering-including-full-exercise-of-overallotment-option/ 2023-12-21T21:00:00+00:00 https://biodexapharma.com/wp-content/uploads/Biodexa-Pharmaceuticals-PLC-no22sj.gif https://biodexapharma.com/biodexa-appoints-ann-merchant-to-the-board-of-directors/ 2023-12-29T09:05:00+00:00 https://biodexapharma.com/wp-content/uploads/Biodexa-Pharmaceuticals-PLC-6hAAKX.gif https://biodexapharma.com/biodexa-ceo-issues-shareholder-letter-highlighting-progress-in-2023-and-expected-milestones-in-2024/ 2024-01-22T13:30:00+00:00 https://biodexapharma.com/wp-content/uploads/image1-vVDZZP.png https://biodexapharma.com/biodexa-announces-allowance-of-u-s-patent-covering-tolimidone/ 2024-02-07T13:30:00+00:00 https://biodexapharma.com/wp-content/uploads/Biodexa-Pharmaceuticals-PLC-0oqRzU.gif https://biodexapharma.com/biodexa-reports-12-month-survival-in-magic-g1-study-of-mtx110-in-recurrent-glioblastoma-patients/ 2024-02-08T13:30:00+00:00 https://biodexapharma.com/wp-content/uploads/Biodexa-Pharmaceuticals-PLC-SeRsWB.gif https://biodexapharma.com/biodexa-announces-positive-top-line-phase-i-clinical-trial-results-for-diffuse-midline-glioma-and-provides-rd-update/ 2024-02-23T13:30:00+00:00 https://biodexapharma.com/wp-content/uploads/Biodexa-Pharmaceuticals-PLC-gp62pB.gif https://biodexapharma.com/preliminary-results-for-the-year-ended-31-december-2023/ 2024-04-19T12:00:00+00:00 https://biodexapharma.com/wp-content/uploads/image1-gS0GUP.png https://biodexapharma.com/biodexa-enters-into-exclusive-license-to-erapa-a-phase-3-ready-asset-for-the-treatment-of-familial-adenomatous-polyposis-fap-2/ 2024-04-26T12:30:00+00:00 https://biodexapharma.com/wp-content/uploads/Biodexa-Pharmaceuticals-PLC-SNmfxQ.gif https://biodexapharma.com/biodexa-enters-into-exclusive-license-to-erapa-a-phase-3-ready-asset-for-the-treatment-of-familial-adenomatous-polyposis-fap/ 2024-04-26T12:30:00+00:00 https://biodexapharma.com/wp-content/uploads/Biodexa-Pharmaceuticals-PLC-SNmfxQ.gif https://biodexapharma.com/biodexas-licensor-emtora-to-announce-phase-2-clinical-trial-results-of-erapa-in-familial-adenomatous-polyposis-to-be-presented-at-prestigious-2024-digestive-disease-week-annual-meeti/ 2024-04-30T15:52:00+00:00 https://biodexapharma.com/wp-content/uploads/Biodexa-Pharmaceuticals-PLC-4tNqF3.gif https://biodexapharma.com/posting-of-annual-report-notice-of-agm-total-voting-rights/ 2024-05-15T07:58:00+00:00 https://biodexapharma.com/wp-content/uploads/Biodexa-Pharmaceuticals-PLC-74fCdd.gif https://biodexapharma.com/positive-statistically-significant-phase-2-clinical-trial-results-of-biodexas-newly-licensed-erapa-in-familial-adenomatous-polyposis-fap-scheduled-for-presentation-at-the-2024-dige/ 2024-05-21T12:30:00+00:00 https://biodexapharma.com/wp-content/uploads/image1-4IM2L2.png https://biodexapharma.com/biodexa-announces-7-million-of-gross-proceeds-from-warrant-exercises/ 2024-05-22T12:30:00+00:00 https://biodexapharma.com/wp-content/uploads/Biodexa-Pharmaceuticals-PLC-YYW5i9.gif https://biodexapharma.com/twelve-month-phase-2-clinical-trial-results-of-erapa-in-familial-adenomatous-polyposis-fap-to-be-presented-at-prestigious-biennial-insight-2024-meeting-in-barcelona/ 2024-06-10T12:30:00+00:00 https://biodexapharma.com/wp-content/uploads/Biodexa-Pharmaceuticals-PLC-1Y6D30.gif https://biodexapharma.com/results-of-annual-general-meeting/ 2024-06-13T13:35:00+00:00 https://biodexapharma.com/wp-content/uploads/Biodexa-Pharmaceuticals-PLC-IsQWCp.gif https://biodexapharma.com/biodexa-announces-positive-phase-2-clinical-trial-results-of-erapa-at-12-months-in-familial-adenomatous-polyposis-fap/ 2024-06-24T12:30:00+00:00 https://biodexapharma.com/wp-content/uploads/Biodexa-Pharmaceuticals-PLC-ymDuRl.gif https://biodexapharma.com/positive-phase-1-clinical-data-of-mtx110-in-dmg-brain-cancer-demonstrating-increased-survival-presented-at-ispno-2024/ 2024-07-02T12:30:00+00:00 https://biodexapharma.com/wp-content/uploads/Biodexa-Pharmaceuticals-PLC-4N7BPW.gif https://biodexapharma.com/biodexa-announces-phase-2a-study-of-tolimidone-in-type-1-diabetes-approved-by-health-canada/ 2024-07-16T12:30:00+00:00 https://biodexapharma.com/wp-content/uploads/Biodexa-Pharmaceuticals-PLC-ludbWG.gif https://biodexapharma.com/announces-pricing-of-5-0-million-registered-direct-offering-and-concurrent-private-placement/ 2024-07-19T12:30:00+00:00 https://biodexapharma.com/wp-content/uploads/Biodexa-Pharmaceuticals-PLC-QlqVHo.gif https://biodexapharma.com/announces-closing-of-5-0-million-registered-direct-offering-and-concurrent-private-placement/ 2024-07-23T12:30:00+00:00 https://biodexapharma.com/wp-content/uploads/Biodexa-Pharmaceuticals-PLC-eqDMgA.gif https://biodexapharma.com/receipt-of-nasdaq-delisting-determination-plans-to-appeal-2/ 2024-08-30T20:30:00+00:00 https://biodexapharma.com/wp-content/uploads/Biodexa-Pharmaceuticals-PLC-FAU1pT.gif https://biodexapharma.com/announces-payment-of-3-0mm-final-match-payment-enabling-access-to-remainder-of-17-0mm-cprit-grant/ 2024-09-16T12:30:00+00:00 https://biodexapharma.com/wp-content/uploads/Biodexa-Pharmaceuticals-PLC-r1UCmU.gif https://biodexapharma.com/adr-ratio-change-2/ 2024-09-19T20:30:00+00:00 https://biodexapharma.com/wp-content/uploads/Biodexa-Pharmaceuticals-PLC-Ds4dwP.gif https://biodexapharma.com/interim-results-for-the-six-months-ended-june-30-2024/ 2024-09-26T12:30:00+00:00 https://biodexapharma.com/wp-content/uploads/picture1-FOXt3R.png https://biodexapharma.com/biodexa-provides-update-on-progression-free-and-overall-survival-in-phase-1-study-of-mtx110-in-recurrent-glioblastoma/ 2024-10-04T12:30:00+00:00 https://biodexapharma.com/wp-content/uploads/Biodexa-Pharmaceuticals-PLC-ljq5it.gif https://biodexapharma.com/biodexa-announces-successful-appeal-of-nasdaq-delisting/ 2024-10-15T20:15:00+00:00 https://biodexapharma.com/wp-content/uploads/Biodexa-Pharmaceuticals-PLC-8GuEAx.gif https://biodexapharma.com/notice-of-general-meeting/ 2024-11-07T21:30:00+00:00 https://biodexapharma.com/wp-content/uploads/Biodexa-Pharmaceuticals-PLC-WGg0ng.gif https://biodexapharma.com/biodexa-pharmaceuticals-plc-biodexa-or-the-company-regains-compliance-for-continued-listing-on-nasdaq/ 2024-11-12T13:48:00+00:00 https://biodexapharma.com/wp-content/uploads/Biodexa-Pharmaceuticals-PLC-VgfTLE.gif https://biodexapharma.com/result-of-general-meeting/ 2024-11-22T13:30:00+00:00 https://biodexapharma.com/wp-content/uploads/Biodexa-Pharmaceuticals-PLC-MEEtTh.gif https://biodexapharma.com/biodexa-strengthens-management-team-appointment-of-dr-gary-a-shangold-as-chief-medical-officer/ 2025-01-22T13:30:00+00:00 https://biodexapharma.com/wp-content/uploads/Biodexa-Pharmaceuticals-PLC-e4oMcW.gif https://biodexapharma.com/biodexa-receives-us-fda-fast-track-designation-for-erapa-in-familial-adenomatous-polyposis/ 2025-02-10T13:30:00+00:00 https://biodexapharma.com/wp-content/uploads/Biodexa-Pharmaceuticals-PLC-LNFWZG.gif https://biodexapharma.com/biodexa-pharmaceuticals-plc-to-present-at-the-emerging-growth-conference-on-february-19-2025/ 2025-02-13T13:30:00+00:00 https://biodexapharma.com/wp-content/uploads/Biodexa-Pharmaceuticals-PLC-k6KV5g.gif https://biodexapharma.com/biodexa-announces-allowance-of-u-s-patent-covering-oral-rapamycin-nanoparticle-preparations-erapa-and-use/ 2025-02-24T13:30:00+00:00 https://biodexapharma.com/wp-content/uploads/Biodexa-Pharmaceuticals-PLC-Uv7xIt.gif https://biodexapharma.com/biodexa-announces-appointment-of-precision-for-medicine-llc-as-cro-for-european-component-of-phase-3-study-of-erapa-in-fap/ 2025-03-06T13:30:00+00:00 https://biodexapharma.com/wp-content/uploads/Biodexa-Pharmaceuticals-PLC-jPwi1U.gif https://biodexapharma.com/biodexa-announces-successful-outcome-of-a-type-c-meeting-with-fda-regarding-the-phase-3-program-for-erapa-in-fap/ 2025-03-10T12:30:00+00:00 https://biodexapharma.com/wp-content/uploads/Biodexa-Pharmaceuticals-PLC-JdTG2x.gif https://biodexapharma.com/preliminary-results-for-the-year-ended-31-december-2024/ 2025-04-11T12:30:00+00:00 https://biodexapharma.com/wp-content/uploads/image1-zsqw1j.png https://biodexapharma.com/notice-of-general-meeting-2/ 2025-04-17T12:30:00+00:00 https://biodexapharma.com/wp-content/uploads/Biodexa-Pharmaceuticals-PLC-WGg0ng.gif https://biodexapharma.com/result-of-general-meeting-2/ 2025-05-02T20:30:00+00:00 https://biodexapharma.com/wp-content/uploads/Biodexa-Pharmaceuticals-PLC-MEEtTh.gif https://biodexapharma.com/biodexa-receives-orphan-drug-designation-in-europe-for-erapa-in-fap/ 2025-05-12T12:30:00+00:00 https://biodexapharma.com/wp-content/uploads/Biodexa-Pharmaceuticals-PLC-GUxMc5.gif https://biodexapharma.com/biodexa-announces-award-of-additional-3-0m-grant-from-cprit-to-support-registrational-erapa-phase-3-program-in-fap-brings-total-cprit-grant-funding-for-erapa-phase-3-program-to-20-0m/ 2025-05-22T12:30:00+00:00 https://biodexapharma.com/wp-content/uploads/Biodexa-Pharmaceuticals-PLC-LuHuJb.gif https://biodexapharma.com/biodexa-pharmaceuticals-plc-biodexa-or-the-company-notice-of-general-meeting/ 2025-05-22T20:30:00+00:00 https://biodexapharma.com/wp-content/uploads/Biodexa-Pharmaceuticals-PLC-mbc8Ys.gif https://biodexapharma.com/shareholder-update/ 2025-05-30T12:30:00+00:00 https://biodexapharma.com/wp-content/uploads/Biodexa-Pharmaceuticals-PLC-pHiJzB.gif https://biodexapharma.com/biodexa-announces-recruitment-of-first-patient-in-phase-2-study-of-tolimidone-in-type-1-diabetes/ 2025-06-04T12:30:00+00:00 https://biodexapharma.com/wp-content/uploads/Biodexa-Pharmaceuticals-PLC-0Gwg3z.gif https://biodexapharma.com/result-of-general-meeting-3/ 2025-06-11T20:30:00+00:00 https://biodexapharma.com/wp-content/uploads/Biodexa-Pharmaceuticals-PLC-MEEtTh.gif https://biodexapharma.com/biodexa-announces-activation-of-first-clinical-study-site-for-phase-3-serenta-trial-in-familial-adenomatous-polyposis-fap/ 2025-06-25T12:30:00+00:00 https://biodexapharma.com/wp-content/uploads/Biodexa-Pharmaceuticals-PLC-zTYE74.gif https://biodexapharma.com/results-of-annual-general-meeting-2/ 2025-06-27T12:30:00+00:00 https://biodexapharma.com/wp-content/uploads/Biodexa-Pharmaceuticals-PLC-IsQWCp.gif https://biodexapharma.com/biodexa-unveils-serenta-as-the-name-of-its-upcoming-phase-3-study-in-familial-adenomatous-polyposis-fap/ 2025-07-01T12:25:14+00:00 https://biodexapharma.com/wp-content/uploads/Biodexa-Pharmaceuticals-PLC-Wo4fY9.gif https://biodexapharma.com/biodexa-announces-filing-of-cta-in-europe-for-phase-3-serenta-trial-in-familial-adenomatous-polyposis-fap/ 2025-07-14T12:30:00+00:00 https://biodexapharma.com/wp-content/uploads/Biodexa-Pharmaceuticals-PLC-1OH9xQ.gif https://biodexapharma.com/adr-ratio-change-3/ 2025-07-15T20:30:00+00:00 https://biodexapharma.com/wp-content/uploads/Biodexa-Pharmaceuticals-PLC-Ds4dwP.gif https://biodexapharma.com/adr-ratio-change-effective/ 2025-07-31T13:30:00+00:00 https://biodexapharma.com/wp-content/uploads/Biodexa-Pharmaceuticals-PLC-CVrKsQ.gif https://biodexapharma.com/biodexa-announces-enrolment-of-first-patients-into-pivotal-phase-3-serenta-trial-in-familial-adenomatous-polyposis-fap/ 2025-08-18T12:30:00+00:00 https://biodexapharma.com/wp-content/uploads/Biodexa-Pharmaceuticals-PLC-bDaire.gif https://biodexapharma.com/interim-results-for-the-six-months-ended-june-30-2025/ 2025-09-12T12:30:00+00:00 https://biodexapharma.com/wp-content/uploads/image1-0ipsum.png https://biodexapharma.com/biodexa-to-host-breakfast-symposium-on-fap-mechanisms-and-chemoprevention-trial-issues-at-cga-igc-conference-on-october-11-2025/ 2025-10-06T12:30:00+00:00 https://biodexapharma.com/wp-content/uploads/Biodexa-Pharmaceuticals-PLC-GTKgri.gif https://biodexapharma.com/biodexa-announces-approval-of-cta-in-europe-for-phase-3-serenta-trial-in-fap-first-european-patient-expected-to-be-enrolled-in-4q-2025-addressable-us-european-market-put-at-7-billion/ 2025-11-03T13:30:00+00:00 https://biodexapharma.com/wp-content/uploads/Biodexa-Pharmaceuticals-PLC-l5ZlOP.gif https://biodexapharma.com/biodexa-activates-first-european-site-for-registrational-phase-3-serenta-trial-in-fap/ 2025-11-24T13:30:00+00:00 https://biodexapharma.com/wp-content/uploads/Biodexa-Pharmaceuticals-PLC-kGIbyb.gif https://biodexapharma.com/biodexa-announces-enrolment-of-first-european-patients-into-pivotal-phase-3-serenta-trial-in-fap/ 2025-12-01T13:30:00+00:00 https://biodexapharma.com/wp-content/uploads/Biodexa-Pharmaceuticals-PLC-nbGner.gif https://biodexapharma.com/biodexa-announces-pricing-of-10-million-public-offering/ 2025-12-18T13:30:00+00:00 https://biodexapharma.com/biodexa-announces-pricing-of-10-million-public-offering-2/ 2025-12-18T13:30:00+00:00 https://biodexapharma.com/wp-content/uploads/Biodexa-Pharmaceuticals-PLC-pbSQ4R.gif https://biodexapharma.com/biodexa-announces-pricing-of-10-million-public-offering-3/ 2025-12-18T13:30:00+00:00 https://biodexapharma.com/wp-content/uploads/Biodexa-Pharmaceuticals-PLC-pbSQ4R.gif https://biodexapharma.com/appointment-of-fiona-sharp-to-the-board-as-chief-financial-officer-and-company-secretary/ 2026-01-05T13:30:00+00:00 https://biodexapharma.com/wp-content/uploads/Biodexa-Pharmaceuticals-PLC-VTHCDG.gif https://biodexapharma.com/biodexa-announces-exclusive-license-of-otsukas-opb-171775-a-potent-phase-1-ready-molecular-glue-for-gist/ 2026-02-04T13:30:00+00:00 https://biodexapharma.com/wp-content/uploads/image1-DPdJwW.png https://biodexapharma.com/biodexa-announces-support-for-lifes-a-polyp-foundation-first-u-s-patient-advocacy-group-for-fap-patients/ 2026-03-09T12:30:00+00:00 https://biodexapharma.com/wp-content/uploads/Biodexa-Pharmaceuticals-PLC-HyIcOr.gif https://biodexapharma.com/adr-ratio-change-4/ 2026-03-18T21:00:00+00:00 https://biodexapharma.com/wp-content/uploads/Biodexa-Pharmaceuticals-PLC-Ds4dwP.gif https://biodexapharma.com/biodexa-launches-global-early-access-program-for-erapa-for-fap-patients-through-strategic-partnership-with-tanner-pharma-group/ 2026-03-23T12:30:00+00:00 https://biodexapharma.com/wp-content/uploads/Biodexa-Pharmaceuticals-PLC-jcfNB2.gif https://biodexapharma.com/preliminary-results-for-the-year-ended-31-december-2025/ 2026-03-27T21:00:00+00:00 https://biodexapharma.com/wp-content/uploads/image1-H1A47X.png https://biodexapharma.com/biodexa-announces-partnership-with-syngene-to-manufacture-mtx240-gmp-clinical-trial-supplies/ 2026-04-02T12:30:00+00:00 https://biodexapharma.com/wp-content/uploads/Biodexa-Pharmaceuticals-PLC-SZLGbu.gif https://biodexapharma.com/biodexa-issues-letter-to-shareholders/ 2026-05-14T12:30:00+00:00 https://biodexapharma.com/wp-content/uploads/Biodexa-Pharmaceuticals-PLC-gaHmoV.gif https://biodexapharma.com/postponement-and-re-scheduling-of-annual-general-meeting/ 2026-06-17T20:30:00+00:00 https://biodexapharma.com/wp-content/uploads/Biodexa-Pharmaceuticals-PLC-7QHKPk.gif https://biodexapharma.com/approval-from-health-canada-to-expand-serenta-registrational-phase-3-trial-in-fap-and-update-on-serenta-progress/ 2026-06-29T12:30:00+00:00 https://biodexapharma.com/wp-content/uploads/Biodexa-Pharmaceuticals-PLC-Wsu8Yg.gif https://biodexapharma.com/biodexa-announces-pricing-of-3-5-million-registered-direct-offering-concurrent-private-placement-of-pre-funded-warrants-and-warrants/ 2026-06-30T12:00:00+00:00 https://biodexapharma.com/wp-content/uploads/Biodexa-Pharmaceuticals-PLC-9OzQiu.gif https://biodexapharma.com/result-of-annual-general-meeting/ 2026-06-30T20:30:00+00:00 https://biodexapharma.com/wp-content/uploads/Biodexa-Pharmaceuticals-PLC-GSg3uk.gif https://biodexapharma.com/biodexa-lance-des-activites-de-soutien-aux-patients-atteints-de-polypose-adenomateuse-familiale-paf-et-aux-centres-de-traitement-en-france/ 2026-07-29T11:19:00+00:00 https://biodexapharma.com/wp-content/uploads/Biodexa-Pharmaceuticals-PLC-7ukKnH.gif https://biodexapharma.com/biodexa-initiates-support-activities-for-fap-patients-and-treatment-centers-in-france/ 2026-07-29T12:30:00+00:00 https://biodexapharma.com/wp-content/uploads/Biodexa-Pharmaceuticals-PLC-Y7WcNT.gif https://biodexapharma.com/result-of-general-meeting-4/ 2026-07-29T20:30:00+00:00 https://biodexapharma.com/wp-content/uploads/Biodexa-Pharmaceuticals-PLC-MEEtTh.gif https://biodexapharma.com/biodexa-announces-major-milestone-for-its-serenta-registrational-phase-3-trial-in-fap-2/ 2026-08-19T12:30:00+00:00 https://biodexapharma.com/wp-content/uploads/Biodexa-Pharmaceuticals-PLC-W5f3Ru.gif https://biodexapharma.com/biodexa-announces-major-milestone-for-its-serenta-registrational-phase-3-trial-in-fap/ 2026-08-19T12:30:00+00:00 https://biodexapharma.com/wp-content/uploads/Biodexa-Pharmaceuticals-PLC-W5f3Ru.gif